AU2022419588A1 - Fitusiran for use in improving patient-reported outcome in hemophilia patients - Google Patents

Fitusiran for use in improving patient-reported outcome in hemophilia patients Download PDF

Info

Publication number
AU2022419588A1
AU2022419588A1 AU2022419588A AU2022419588A AU2022419588A1 AU 2022419588 A1 AU2022419588 A1 AU 2022419588A1 AU 2022419588 A AU2022419588 A AU 2022419588A AU 2022419588 A AU2022419588 A AU 2022419588A AU 2022419588 A1 AU2022419588 A1 AU 2022419588A1
Authority
AU
Australia
Prior art keywords
fitusiran
qol
patient
hemophilia
questionnaire
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022419588A
Other languages
English (en)
Inventor
Shauna Andersson
Jose BARTELT-HOFER
Pronabesh Dasmahapatra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AU2022419588A1 publication Critical patent/AU2022419588A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022419588A 2021-12-22 2022-12-22 Fitusiran for use in improving patient-reported outcome in hemophilia patients Pending AU2022419588A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202163293070P 2021-12-22 2021-12-22
US63/293,070 2021-12-22
US202263305550P 2022-02-01 2022-02-01
US63/305,550 2022-02-01
US202263335535P 2022-04-27 2022-04-27
US63/335,535 2022-04-27
US202263359717P 2022-07-08 2022-07-08
US63/359,717 2022-07-08
US202263382223P 2022-11-03 2022-11-03
US63/382,223 2022-11-03
US202263386489P 2022-12-07 2022-12-07
US63/386,489 2022-12-07
PCT/US2022/082213 WO2023122713A1 (en) 2021-12-22 2022-12-22 Fitusiran for use in improving patient-reported outcome in hemophilia patients

Publications (1)

Publication Number Publication Date
AU2022419588A1 true AU2022419588A1 (en) 2024-08-01

Family

ID=85227438

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022419588A Pending AU2022419588A1 (en) 2021-12-22 2022-12-22 Fitusiran for use in improving patient-reported outcome in hemophilia patients

Country Status (10)

Country Link
US (1) US20250064842A1 (cg-RX-API-DMAC7.html)
EP (1) EP4452280A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025500412A (cg-RX-API-DMAC7.html)
KR (1) KR20240138572A (cg-RX-API-DMAC7.html)
AU (1) AU2022419588A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243297A1 (cg-RX-API-DMAC7.html)
IL (1) IL313677A (cg-RX-API-DMAC7.html)
MX (1) MX2024007894A (cg-RX-API-DMAC7.html)
TW (1) TW202342065A (cg-RX-API-DMAC7.html)
WO (1) WO2023122713A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025171279A1 (en) * 2024-02-09 2025-08-14 Genzyme Corporation Treatment of hemophilia with fitusiran

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
JP2020530442A (ja) 2017-07-10 2020-10-22 ジェンザイム・コーポレーション 血友病を有する対象の出血事象を処置するための方法および組成物
WO2022120291A1 (en) * 2020-12-06 2022-06-09 Genzyme Corporation Treatment of hemophilia with fitusiran

Also Published As

Publication number Publication date
MX2024007894A (es) 2024-08-20
JP2025500412A (ja) 2025-01-09
KR20240138572A (ko) 2024-09-20
WO2023122713A1 (en) 2023-06-29
US20250064842A1 (en) 2025-02-27
CA3243297A1 (en) 2023-06-29
TW202342065A (zh) 2023-11-01
EP4452280A1 (en) 2024-10-30
IL313677A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
US20260014188A1 (en) Methods and compositions for treating hemophilia
US20240027478A1 (en) Treatment of hemophilia with fitusiran
US20240000744A1 (en) Treatment of Hemophilia with Fitusiran
WO2022120291A1 (en) Treatment of hemophilia with fitusiran
Gualtierotti et al. Gene therapy in hemophilia: the dawn of a new era
US20250064842A1 (en) Fitusiran for Use in Improving Patient-Reported Outcome in Hemophilia Patients
TW202525306A (zh) 用非妥西蘭(fitusiran)治療a型血友病
TW202417014A (zh) 於小兒患者中以非妥西蘭治療血友病
US20240417739A1 (en) Compositions and methods for treatment of bleeding disorders
CN118434425A (zh) 用于改善血友病患者的患者报告结局的非妥西兰
WO2025171279A1 (en) Treatment of hemophilia with fitusiran
TW202308659A (zh) 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸
Lyseng-Williamson Nanofiltered Human C1 Inhibitor Concentrate (Cinryze [superscript]?[/superscript])